This study is currently not recruiting participants.

A Randomized Open-Label Phase 2 Study of EC145 Single-Agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptors Positive [FR(++)] Second Line NSCLC

Investigating the Effects of an Investigational Medication in Advanced Non-Small Cell Lung Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test the effects of EC145 , an experimental drug, given alone or in combination with docetaxel in men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed or recurred (came b

Detailed description of study

The purpose of this study is to test the effects of EC145 , an experimental drug, given alone or in combination with docetaxel in men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed or recurred (came b

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lung Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication given alone or with another treatment in people with advanced non-small cell lung cancer (NSCLC). NSCLC is a type of lung cancer that has spread or returned after treatment. The study aims to learn how the investigational medication works in controlling the disease.

Participants will receive either the investigational medication alone or in combination with another treatment. The study will involve regular assessments to monitor the effects and any side effects of the treatment. This will help determine the medication's effectiveness and safety.

  • Who can participate: Adults aged 18 and over with locally advanced or metastatic non-small cell lung cancer that has progressed or recurred may be eligible.
  • Study details: Participants will receive either the investigational medication alone or with another treatment, which may include a placebo. The study will include regular check-ups to monitor health and treatment effects.
Updated on 19 Feb 2024. Study ID: 1208009317

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team